Silibinin Effect on Fas/FasL, HMGB1, and CD45 Expressions in a Rat Model Subjected to Liver Ischemia-Reperfusion Injury

REFERENCES

• Abu-Amara M, Yang SY, Tapuria N, et al. Liver ischemia/reperfusion injury: processes in inflammatory networks—a review. Liver Transpl. 2010;16(9):1016–1032.
   PubMed Web of Science ®Google Scholar
• Weigand K, Brost S, Steinebrunner N, et al. Ischemia/Reperfusion injury in liver surgery and transplantation: pathophysiology. HPB Surg. 2012;2012:176723. doi:10.1155/2012/176723. Epub 2012 May 30.
   PubMedGoogle Scholar
• Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev. 2010;90(3):1165–1194.
   PubMed Web of Science ®Google Scholar
• Guo ZS, Liu Z, Bartlett DL, et al. Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res. 2013;3(1):1–20.
   PubMed Web of Science ®Google Scholar
• Chou DK, Evans JE, Jungalwala FB. Identity of nuclear high-mobility-group protein, HMG-1, and sulfoglucuronyl carbohydrate-binding protein, SBP-1, in brain. J Neurochem. 2001;77(1):120–131.
   PubMed Web of Science ®Google Scholar
• Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev. 2005;15(5): 496–506.
   PubMed Web of Science ®Google Scholar
• Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta. 2010;1799(1–2):149–156.
   PubMed Web of Science ®Google Scholar
• Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immuno. 2010;28:367–388.
   PubMed Web of Science ®Google Scholar
• Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T cell activation. Immunol Cell Biol. 1997;75(5):430–445.
   PubMed Web of Science ®Google Scholar
• Hermiston ML, Zikherman J, Zhu JW. CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells. Immunol Rev. 2009;228(1):288–311. Erratum in: Immunol Rev. 2009;229(1):387
   PubMed Web of Science ®Google Scholar
• Lowell CA. Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. Cold Spring Harb Perspect Biol. 2011;3(3): pii: a002352
   PubMed Web of Science ®Google Scholar
• Bartels M, Biesalski HK, Engelhart K, et al. Pilot study on the effect of parenteral vitamin E on ischemia and reperfusion induced liver injury: a double blind, randomized, placebo-controlled trial. Clin Nutr. 2004;23(6):1360–1370.
   PubMed Web of Science ®Google Scholar
• Cerwenka H, Bacher H, Werkgartner G, et al. Antioxidant treatment during liver resection for alleviation of ischemia– reperfusion injury. Hepatogastroenterology. 1998;45(21):777–782.
   PubMedGoogle Scholar
• Dunschede F, Erbes K, Kircher A, et al. Reduction of ischemia reperfusion injury after liver resection and hepatic inflow occlusion by alpha-lipoic acid in humans. World J Gastroenterol. 2006;12(42):6812–6817.
   PubMed Web of Science ®Google Scholar
• Glantzounis GK, Salacinski HJ, Yang W, et al. The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: a review. Liver Transpl. 2005;11(9):1031–1047.
   PubMed Web of Science ®Google Scholar
• Aldrighetti L, Pulitano C, Arru M, et al. Impact of preoperative steroids administration on ischemia–reperfusion injury and systemic responses in liver surgery: a prospective randomized study. Liver Transpl. 2006;12(6):941–949.
   PubMed Web of Science ®Google Scholar
• Orci LA, Toso C, Mentha G, et al. Systematic review and meta-analysis of the effect of perioperative steroids on ischaemia-reperfusion injury and surgical stress response in patients undergoing liver resection. Br J Surg. 2013;100(5):600–609.
   PubMed Web of Science ®Google Scholar
• Sugawara Y, Kubota K, Ogura T, et al. Protective effect of prostaglandin E1 against ischemia/reperfusion-induced liver injury: results of a prospective, randomized study in cirrhotic patients undergoing subsegmentectomy. J Hepatol. 1998;29(6):969–976.
   PubMed Web of Science ®Google Scholar
• Orii R, Sugawara Y, Hayashida M, et al. Effects of amrinone on ischaemia–reperfusion injury in cirrhotic patients undergoing hepatectomy: a comparative study with prostaglandin E1. Br J Anaesth. 2000;85(3):389–395.
   PubMed Web of Science ®Google Scholar
• Gazák R, Walterová D, Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem. 2007;14(3):315–338.
   PubMed Web of Science ®Google Scholar
• Crocenzi F, Roma M. Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Curr Med. Chem. 2006;13(9):1055–1074.
   PubMed Web of Science ®Google Scholar
• Kroll D, Shaw H, Oberlies N. Milk Thistl Nomenclature: Why it matters in cancer research and pharmacokinetic studies. Int Cancer Ther 2007;6(2):110–119.
   PubMed Web of Science ®Google Scholar
• Abenavoli L, Capasso R, Milic M, et al. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24:1423–1432.
   PubMed Web of Science ®Google Scholar
• Mira L, Silva M, Manso CF. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 1994;48:753–759.
   PubMed Web of Science ®Google Scholar
• Gažák R, Sedmera P, Vrbacký M, et al. Molecular mechanisms of silybin and 2,3-dehydrosilybin antiradical activity—role of individual hydroxyl group. Free Radical Biol Med 2009;46:745–747.
   PubMed Web of Science ®Google Scholar
• Sonnenbichler J, Zetl I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. In: Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological and Structure-Activity Relationship, Cody V, Middleton E, Harborne JB, eds. New York: Alan R Liss Inc.; 1986:319–331.
   Google Scholar
• Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 2008;68:2043–2050.
   PubMed Web of Science ®Google Scholar
• Tyagi A, Singh RP, Ramasamy K, et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res. 2009;2:74–83.
   PubMed Web of Science ®Google Scholar
• Raina K, Agarwal C, Agarwa R. Effect of silibinin in human colorectal cancer cells: Targeting the activation of NF-κB signaling. Mol Carcinog. 2013;52(3):195–206.
   PubMed Web of Science ®Google Scholar
• Nambiar D, Rajamani P, Singh R. Silibinin attenuates ionizing radiation-induced pro-angiogenic response and EMT in prostate cancer. Biochem Biophys Res Comm. 2015;456:262–268.
   PubMed Web of Science ®Google Scholar
• Lim R, Morwood C, Barker G, et al. Effect of silibinin in reducing inflammatory pathways in in vitro and in vivo models of infection-induced preterm birth. PLOS ONE 2014;9:1–13( e92505).
   Web of Science ®Google Scholar
• Kren V, Walterová D. Silybin and silymarin–new effects and applications. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 2005;149(1):29–41.
   PubMedGoogle Scholar
• Morazzoni P, Bombardelli E. Silybum marianum (Carduus marianus). Fitoterapia. 1995;66(1):3–42.
   Google Scholar
• Flora K, Hahn M, Rosen H, et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998;93(2):139–143.
   PubMed Web of Science ®Google Scholar
• Dixit N, Baboota S, Kohli K, et al. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol 2007;39(4):172–179.
   Web of Science ®Google Scholar
• Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007;25(2):139–146.
   PubMed Web of Science ®Google Scholar
• Ting H, Deep G, Agarwal R. Molecular mechanisms of Silibinin-mediated cancer chomoprevention with major emphasis pn prostete cancer. AAPS J 2013;25(3):707–715.
   Web of Science ®Google Scholar
• Rajamanickam S, Kaur M, Velmurugan B, et al. Silibinin suppresses spontaneous tumorigenesis in APCmin/+ Mouse model by modulating beta-catenin pathway. Pharm Res. 2009;26(12):2558–2567.
   PubMed Web of Science ®Google Scholar
• Zholobenko A, Modriansky M. Silymarin and its constituents in cardiac preconditioning. Fitoterapia 2014;97:122–132.
   PubMed Web of Science ®Google Scholar
• Weyhenmeyer R, Mascher H, Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol. 1992;30(4):134–138.
   PubMed Web of Science ®Google Scholar
• Morazzoni PA, Montalbetti S, Malandrino G, Pifferi, Eur. J Drug Metab Pharmacokinet. 1993;18:289–297.
   PubMed Web of Science ®Google Scholar
• Zhu H, Brinda B, Chavin K, et al. An assessment of pharmacokinetics and antioxidant activity of free Silymarin flavonolignans in healthy volunteers: a dose escalation study. Drug Metab Dispos. 2013;41:1679–1685.
   PubMed Web of Science ®Google Scholar
• Theodosiou E, Purchartova K, Stamatis H, et al. Bioavailability of silymarin flavonolignans: drug formulations and biotransformation. Phytochem Rev 2014;13:1–18.
   Web of Science ®Google Scholar
• Wu JW, Lin LC, Hung SC, et al. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal. 2007;45:635–641.
   PubMed Web of Science ®Google Scholar
• Kellici T, Ntountaniotis D, Leonis G, et al. Investigation of the interactions of silybin with 2-hydroxypropyl-β-cyclodextrin through biophysical techniques and computational methods Mol. Pharmaceutics. 2015;12(3):954–965.
   Web of Science ®Google Scholar
• Christodoulou Ei, Kechagia IA, Kostomitsopoulos N, et al. Serum and tissue pharmacokinetics of silibinin after per os and i.v. administration to mice as a HP-β-CD lyophilized product. Int J Pharm. 2015;493:366–373.
   PubMed Web of Science ®Google Scholar
• Figueiras A, Carvalho RA, Ribeiro L, et al. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified β-cyclodextrin. Eur J Pharm Biopharm. 2007;67(2):531−539.
   PubMed Web of Science ®Google Scholar
• Li J, Li RJ, Lv GY, et al. The mechanisms and strategies to protect from ischemia-reperfusion injury. Eur Rev Med Pharmacol Sci. 2015;19(11):2036–2047.
   PubMed Web of Science ®Google Scholar
• Montalvo-Jave EE, Escalante-Tattersfield T, Ortega-Salgado JA, et al. Factors in the pathophysiology of the liver ischemia-reperfusion injury. J Surg Res. 2008;147(1):153–159.
   PubMed Web of Science ®Google Scholar
• Tsalkidou EG, Tsaroucha AK, Chatzaki E, et al. The effects of apigenin on the expression of Fas/FasL apoptotic pathway in warm liver ischemia/reperfusion injury in rats. Bio Med Res Int. 2014; 2014, Article ID 157216, 7p, doi:10.1155/2014/157216.
   PubMed Web of Science ®Google Scholar
• Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med. 2005;201(7):1135–1143.
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002 Jul 11;418(6894):191–195. Erratum in: Nature. 2010;467(7315):622.
   PubMed Web of Science ®Google Scholar
• Zhai Y, Busuttil RW, Kupiec-Weglinski JW. Liver ischemia and reperfusion injury: new insights into mechanisms of innate—adaptive immune-mediated tissue inflammation. Am J Transplant. 2011;11(8):1563–1569.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang L, Tao K, et al. Protective effects of hydrogen enriched saline on liver ischemia reperfusion injury by reducing oxidative stress and HMGB1 release. BMC Gastroenterol. 2014;14:12.
   PubMed Web of Science ®Google Scholar
• Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants (Basel). 2015;4(1):204–247.
   PubMedGoogle Scholar
• Kaplan R, Morse B, Huebner K, et al. Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine-phosphatases expressed in brain. Proc Natl Acad Sci U S A. 1990;87(18):7000–7004.
   PubMed Web of Science ®Google Scholar
• Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T cell activation. Immunol Cell Biol. 1997;75(5):430–445.
   PubMed Web of Science ®Google Scholar
• Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene, 2004;23(48):7990–8000.
   PubMed Web of Science ®Google Scholar
• Zhang S, Morris ME. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res. 2003;20(8):1184–1191.
   PubMed Web of Science ®Google Scholar
• Rolo AP, Oliveira PJ, Moreno AJ, et al. Protection against post-ischemic mitochondrial injury in rat liver by silymarin or TUDC. Hepatol Res. 2003;26(3):217–224.
   PubMed Web of Science ®Google Scholar
• Ligeret H, Brault A, Vallerand D, et al. Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury. J Ethnopharmacol. 2008;115(3):507–514.
   PubMed Web of Science ®Google Scholar
• Wu CG, Chamuleau RA, Bosch KS, et al. Protective effect of silymarin on rat liver injury induced by ischemia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(5):259–263.
   PubMedGoogle Scholar
• Wu JP, Tsai CC, Yeh YL, et al. Silymarin accelerates liver regeneration after partial hepatectomy. Evid Based Complement Alternat Med. 2015;2015:603529.
   PubMed Web of Science ®Google Scholar
• Woo SM, Min KJ, Chae IG, et al. Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways. Mol Carcinog. 2015;54(3):216–228. doi:10.1002/mc.22092.
   PubMed Web of Science ®Google Scholar
• Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011;17(18):2288–2301.
   PubMed Web of Science ®Google Scholar